Busch, CatharinaOkada, MaliZur, DinahFraser-Bell, SamanthaRodríguez-Valdés, PatricioCebeci, ZaferLupidi, MarcoFung, Adrian T.Gabrielle, Pierre-HenryGiancipoli, ErmeteChaikitmongkol, VorapornLaíns, InêsSantos, Ana RitaKunavisarut, ParadeeSala-Puigdollers, AnnaChhablani, JayOzimek, MalgorzataHilely, AssafDegenhardt, ValentinLoewenstein, AnatIglicki, MatiasRehak, Matus2021-02-092022-11-012020-11Busch, C., Okada, M., Zur, D., Fraser‐Bell, S., Rodríguez‐Valdés, P.J., Cebeci, Z., Lupidi, M., Fung, A.T., Gabrielle, P.‐H., Giancipoli, E., Chaikitmongkol, V., Laíns, I., Santos, A.R., Kunavisarut, P., Sala‐Puigdollers, A., Chhablani, J., Ozimek, M., Hilely, A., Degenhardt, V., Loewenstein, A., Iglicki, M., Rehak, M. and (2020), Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmol, 98: e801-e806. https://doi.org/10.1111/aos.14390http://hdl.handle.net/10400.22/16932Patients with DMO and good baseline VA, managed by observation, are of increased risk for VA loss if DRIL, HRF and EZ disruption are present at baseline. Earlier treatment with anti‐VEGF in these patients may potentially decrease the risk of VA loss at 12 months.engDiabetesDiabetic macular oedemaDiabetic retinopathyGood visual acuityIntravitreal therapyMacular OedemaObservationjournal article10.1111/aos.1439